Table 3. Logistic regression of presence of problems in mobility, self care and usual activities (EQ5D) and presence of anxiety and depression (HADS) by BMI tertiles and by continuous BMI.
1st tertile ( ≤ 42.99) | 2nd tertile (43.00 − 48.61) | 3rd tertile ( ≥ 48.62) | P for linear trend | Continuous BMI | ||
Odds ratio (95% CI) | ||||||
Mobility problems | Univariate | 1.00 | 1.25 (0.64 − 2.44) | 2.95 (1.40 − 6.22)* | 0.004 | 1.07 (1.02 – 1.12)* |
Model 1 | 1.00 | 1.32 (0.66 – 2.63) | 2.83 (1.31 – 6.15)* | 0.008 | 1.07 (1.02 – 1.12)* | |
Model 2 | 1.00 | 1.64 (0.78 – 3.44) | 3.44 (1.47 – 8.05)* | 0.009 | 1.08 (1.03 – 1.13)* | |
Self care problems | Univariate | 1.00 | 0.84 (0.41 – 1.72) | 2.19 (1.09 – 4.39)* | 0.018 | 1.05 (1.01 – 1.09)* |
Model 1 | 1.00 | 0.88 (0.42 – 1.88) | 2.05 (0.98 – 4.27) | 0.044 | 1.05 (1.01 – 1.10)* | |
Model 2 | 1.00 | 0.89 (0.41 – 1.96) | 1.87 (0.86 – 4.09) | 0.104 | 1.05 (1.00 – 1.09)* | |
Problems performing usual activities | Univariate | 1.00 | 1.71 (0.86 – 3.37) | 2.65 (1.27 – 5.52)* | 0.008 | 1.05 (1.01 – 1.10)* |
Model 1 | 1.00 | 1.73 (0.86 – 3.44) | 2.48 (1.17 – 5.23)* | 0.016 | 1.05 (1.01 – 1.10)* | |
Model 2 | 1.00 | 2.04 (0.98 – 4.26) | 2.45 (1.10 – 5.46)* | 0.040 | 1.05 (1.00 – 1.10)* | |
Anxiety | Univariate | 1.00 | 0.75 (0.37 – 1.51) | 0.73 (0.36 – 1.45) | 0.409 | 0.98 (0.95 – 1.02) |
Model 1 | 1.00 | 0.68 (0.33 – 1.42) | 0.74 (0.35 – 1.54) | 0.460 | 0.98 (0.94 – 1.01) | |
Model 2 | 1.00 | 0.71 (0.34 – 1.50) | 0.81 (0.37 – 1.74) | 0.633 | 0.98 (0.95 – 1.02) | |
Depression | Univariate | 1.00 | 1.57 (0.78 – 3.15) | 1.00 (0.51 – 1.98) | 0.958 | 1.00 (0.96 – 1.03) |
Model 1 | 1.00 | 1.59 (0.79 – 3.20) | 1.06 (0.53 – 2.11) | 0.910 | 1.00 (0.96 – 1.03) | |
Model 2 | 1.00 | 1.65 (0.80 – 3.40) | 1.26 (0.61 – 2.62) | 0.550 | 1.00 (0.97 – 1.04) |
Presence of problems defined as level 2 (some problems) and level 3 (extreme problems) scores on EQ5D-3L; Presence of anxiety and depression defined as HADS anxiety subscale score ≥8.
* P<0.05.
**P<0.001.
Model 1 adjusting for age and sex.
Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease.